The ELF3 Antibody, FITC conjugated is a fluorescently labeled primary antibody designed to detect the E74-like factor 3 (ELF3) transcription factor. ELF3, also known as ESE-1, is a member of the ETS family of transcription factors and plays critical roles in epithelial cell differentiation, inflammation, and cancer progression. The antibody is conjugated with Fluorescein Isothiocyanate (FITC), a green-fluorescing dye optimized for immunofluorescence (IF), immunohistochemistry (IHC), and other imaging-based techniques.
Conjugation: FITC excitation/emission peaks at ~498 nm/~519 nm, enabling bright, stable fluorescence in microscopy.
Reactivity: Detects human and mouse ELF3 (cross-reactivity varies by vendor).
Applications:
Immunofluorescence (IF): Localizes ELF3 in fixed cells/tissues.
Immunohistochemistry (IHC): Identifies ELF3 expression in paraffin-embedded sections.
Western Blot (WB): Validates protein expression in lysates.
Multiple vendors offer ELF3 antibodies with FITC conjugation, differing in host species, dilution ranges, and validation:
Lung Cancer: ELF3 inhibition reduces viability in NSCLC cells with EGFR mutations (e.g., L858R/T790M), suggesting therapeutic potential .
Prostate Cancer: ELF3 represses androgen receptor (AR) activity, potentially modulating castration-resistant prostate cancer .
Transcriptional Regulation: ELF3 binds AT-rich DNA and interacts with histone acetyltransferases (e.g., EP300, CREBBP) .
Inflammation: Induces genes like COX2 and Ang1 in response to inflammatory signals .